- AuthorisedTherapeutic use (Phase IV)
Antibiotic therapy vs. placebo in the treatment of acute uncomplicated appendicitis: a prospective randomized double-blind placebo-controlled trial - APPAC III
This study, called APPAC III, is looking at whether antibiotics can successfully treat acute appendicitis without surgery. We're comparing antibiotics to a dummy treatment to see if patients get better and avoid an operation. It's for adults with uncomplicated appendicitis.
For: Uncomplicated acute appendicitisFinland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A single center, open-label pilot study in healthy subjects using dermal open flow microperfusion to collect body fluids for bioanalytical matrix validation and to explore the effects of topical product removal on dermal kinetics
This study is looking at how a cream with metronidazole gets into and out of your skin, and how removing the cream changes this. It's a small study in healthy people to help improve future research methods.
For: No medical condition is being investigated in this clinical trial.Austria - AuthorisedTherapeutic use (Phase IV)
Optimizing the antibiotic treatment of uncomplicated acute appendicitis: a prospective randomized multicenter study
This study looks at different antibiotic treatments for mild appendicitis. Researchers want to see which antibiotics work best to avoid surgery and prevent the appendicitis from returning for at least a year. It's for adults aged 18 and over.
For: Uncomplicated acute appendicitisFinland - AuthorisedTherapeutic confirmatory (Phase III)
The value of post-operative antibiotic therapy after laparoscopic appendectomy for complicated acute appendicitis (other than for generalized peritonitis): a prospective, randomized, open-label, non-inferiority Phase III study.
This study is looking at whether giving antibiotics after surgery for a complicated appendix reduces new infections. It compares common antibiotics to see which works best for patients aged 18 and over, after keyhole surgery.
For: complicated acute appendicitisFrance - AuthorisedTherapeutic use (Phase IV)
Acute appendicitis and microbiota – etiology and effects of the antimicrobial treatment - MAPPAC
This study looks at how antibiotics for appendicitis affect the helpful germs (microbiota) in your gut. It aims to see if certain gut germs are linked to more serious appendicitis and how different antibiotics change them.
For: Uncomplicated acute appendicitis · Complicated acute appendicitisFinland - AuthorisedTherapeutic exploratory (Phase II)
C3601010: A Phase 2A, 2-Part, Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam ± Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment
This study is testing a new combination antibiotic treatment (Aztreonam and Avibactam, sometimes with Metronidazole) for serious bacterial infections in babies up to 9 months old. It aims to see how the medicines work in their bodies and if they are safe.
For: Sepsis · Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment · Complicated Urinary Tract InfectionSlovakia · Greece · Bulgaria - AuthorisedTherapeutic use (Phase IV)
TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial
This study is looking at the best length of antibiotic treatment for liver abscesses, comparing 3 weeks to 6 weeks. It wants to see if shorter treatment is just as effective and safe as longer treatment for patients after their abscess has been drained.
For: Pyogenic liver abscessFrance - AuthorisedTherapeutic use (Phase IV)
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
This study looks at how well antibiotics work in very sick patients. Researchers want to make sure these important medicines reach the right levels in the body to fight serious infections effectively and safely. It's about getting the dose just right.
For: Serious infections in critically ill patients treated with antibioticsFrance